Ajlan Radwan S, Luvisi Joey, Brass Connor
Department of Ophthalmology, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Case Rep Ophthalmol. 2020 Oct 13;11(3):523-527. doi: 10.1159/000508091. eCollection 2020 Sep-Dec.
A 58-year-old Caucasian female presented to the retina service with a 2-week history of bilateral decrease in vision. She had stage 4 renal cell carcinoma with osseous metastasis and choroidal metastasis for which she has been treated with Nivolumab immunotherapy. Her exudative retinal detachments resolved after cessation of Nivolumab in association with subtenon steroids (STK) and intravitreal bevacizumab injections. To the best of our knowledge, this is the first report in the literature describing the resolution of Nivolumab-related exudative retinal detachment after early local therapy using STK injections (10 mg), bevacizumab intravitreal injections, and cessation of Nivolumab. We hope by sharing this report to provide new insight into the management of similar patients.
一名58岁的白种女性因双眼视力下降2周就诊于视网膜专科。她患有4期肾细胞癌伴骨转移和脉络膜转移，已接受纳武单抗免疫治疗。在停用纳武单抗并联合球周类固醇（STK）和玻璃体内注射贝伐单抗后，她的渗出性视网膜脱离得到缓解。据我们所知，这是文献中首次报道在早期采用STK注射（10毫克）、玻璃体内注射贝伐单抗及停用纳武单抗进行局部治疗后，纳武单抗相关的渗出性视网膜脱离得到缓解。我们希望通过分享本报告，为类似患者的管理提供新的见解。
